



**HAL**  
open science

## Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort

Julia Vanlerberghe, Frédéric Dezoteux, Claire Martin, Marie Jachiet, Angèle Soria, Florence Tétart, Anne-Bénédicte Modeste-Duval, Anne-Claire Bursztejn, Laurent Misery, François Aubin, et al.

### ► To cite this version:

Julia Vanlerberghe, Frédéric Dezoteux, Claire Martin, Marie Jachiet, Angèle Soria, et al.. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. *Journal of The American Academy of Dermatology*, 2023, 88 (4), pp.900-904. 10.1016/j.jaad.2022.10.034 . hal-03903864

**HAL Id: hal-03903864**

**<https://univ-rennes.hal.science/hal-03903864v1>**

Submitted on 16 Dec 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Article type: Research Letter**

2  
3 **Title: Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant**  
4 **atopic dermatitis in a real-life French multicenter adult cohort**

5  
6 Vanlerberghe Julia<sup>1</sup>, Dezoteux Frédéric<sup>1</sup> MD, Martin Claire<sup>2</sup>, Jachiet Marie<sup>3</sup> MD, Soria Angèle<sup>4</sup> MD  
7 PhD, Tétart Florence<sup>5</sup> MD, Modeste-Duval Anne-Bénédicte<sup>5</sup> MD, Bursztejn Anne-Claire<sup>6</sup> MD PhD,  
8 Misery Laurent<sup>7</sup> MD PhD, Aubin François<sup>8</sup> MD PhD, Lasek Audrey<sup>9</sup> MD, Leleu Camille<sup>10</sup> MD, Du-  
9 Thanh Aurélie<sup>11</sup> MD, Pasteur Justine<sup>12</sup> MD, Pralong Pauline<sup>13</sup> MD, Nosbaum Audrey<sup>14</sup> MD PhD,  
10 Droitcourt Catherine<sup>15</sup> MD PhD, Viguier Manuelle<sup>16</sup> MD PhD, Tauber Marie<sup>17</sup> MD PhD, Seneschal  
11 Julien<sup>18</sup> MD PhD, Barbarot Sébastien<sup>19</sup> MD PhD, Staumont-Sallé Delphine<sup>1</sup> MD PhD.

12  
13 <sup>1</sup> CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational  
14 Research Institute (INFINITE) F-59000, Lille, France

15 <sup>2</sup> CHU Lille, Department of Biostatistics, F-59000 Lille, France

16 <sup>3</sup> Université de Paris, Faculté de Médecine, AP-HP, Service de Dermatologie, Hôpital Saint-Louis,  
17 Paris, France

18 <sup>4</sup> Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUERP, APHP, Paris, France  
19 Sorbonne Universités Paris, Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris),  
20 INSERM U1135, Paris, France

21 <sup>5</sup> Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France

22 <sup>6</sup> Department of Dermatology, Nancy University Hospital, Nancy, France

23 <sup>7</sup> Department of Dermatology, University Hospital of Brest, Brest, France

24 <sup>8</sup> Service de Dermatologie, Inserm 1098, Centre Hospitalier Régional Universitaire de Besançon,  
25 Université de Franche Comté, Besançon, France

26 <sup>9</sup> Service de Dermatologie, Hôpital St Vincent de Paul, Groupement des Hôpitaux de l'Institut  
27 Catholique de Lille, France

28 <sup>10</sup> Service de Dermatologie, Hôpital Le Bocage, CHU Dijon, France

29 <sup>11</sup> Service de Dermatologie, CHU Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier

30 <sup>12</sup> Dermatology Department, University of Clermont-Ferrand, Clermont-Ferrand, France

31 <sup>13</sup> Dermatology and Allergology Department, Grenoble University Hospital, Grenoble, France

32 <sup>14</sup> Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite,  
33 University of Lyon, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole  
34 Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France

35 <sup>15</sup> Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, UMR\_S 1085, Irset  
36 (Institut de recherche en santé, environnement et travail), EHESP, Inserm, Université de Rennes,  
37 Rennes, France

38 <sup>16</sup> Department of Dermatology, Hôpital Robert Debré, Université de Reims Champagne-Ardenne  
39 and EA 7509 (IRMAIC) Reims, France

40 <sup>17</sup> Dermatology Department, Toulouse University Hospital and Inserm UMR 1291– CNRS, Infinity  
41 (L'Institut Toulousain des Maladies Infectieuses et Inflammatoires), Toulouse, France.

42 <sup>18</sup> Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, CNRS UMR  
43 5164, ImmunoConCept, Université de Bordeaux, Hôpital Saint André, CHU de Bordeaux, France

44 <sup>19</sup> Nantes Université, Department of Dermatology, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000  
45 Nantes, France

46  
47 For the French Group of Research and Study in Atopic Dermatitis (GREAT), the French Society of  
48 Dermatology (SFD).

49  
50 **Corresponding author:**

51 Delphine Staumont-Sallé

52 Service de Dermatologie, Hôpital Huriez, CHU Lille

53 59037 Lille – France

54 Email: [delphine.salle@chru-lille.fr](mailto:delphine.salle@chru-lille.fr)

55 Phone: 0033320444191

56 Fax: 0033320445916

57  
58 **Funding sources:** none

59 **No prior presentation.**

60  
61 **Conflicts of interest:**

62 JV: none.

63 FD: investigator and consultant and speaker for AbbVie, Almirall, Eli Lilly, Janssen, Leo Pharma,  
64 Novartis and Sanofi-Regeneron.

65 CM: none.

66 MJ: investigator and/or consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer,  
67 Galderma and Sanofi-Regeneron.

68 AS: investigator and/or consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Novartis, Pfizer  
69 and Sanofi-Regeneron.

70 FT: investigator and/or speaker and/or consultant for Sanofi-Regeneron.

71 ABDM: investigator and/or speaker and/or consultant for Sanofi-Regeneron.

72 ACB: consultant and/or speaker for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Janssen, Leo  
73 Pharma, Novartis, Pfizer and Sanofi-Regeneron.

74 LM: investigator and/or consultant and/or speaker for AbbVie, Almirall, Amgen, Astra-Zeneca, Eli  
75 Lilly, Galderma, Leo Pharma, Novartis, Pfizer and Sanofi-Regeneron.

76 FA: investigator and/or consultant and/or speaker for AbbVie, Almirall, Amgen, Astra-Zeneca, BMS,  
77 Eli Lilly, Galderma, Leo Pharma, MSD, Novartis, Pfizer, Pierre Fabre and Sanofi-Regeneron.

78 AL: investigator and/or speaker and/or consultant for Sanofi-Regeneron.

79 CL: investigator for Leo Pharma, consultant and/or speaker for AbbVie, Amgen, Eli Lilly, Novartis,  
80 and Sanofi-Regeneron.

81 ADT: investigator and/or consultant and/or speaker for AbbVie, Amgen, Eli Lilly, Leo Pharma,  
82 Novartis, Pfizer, Takeda, BioCryst and Sanofi-Regeneron.

83 JP: investigator and/or consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Novartis, Pfizer,  
84 and Sanofi-Regeneron.

85 PP: investigator for Eli Lilly, speaker for AbbVie, Sanofi-Regeneron.

86 AN: investigator and/or consultant and/or speaker for AbbVie, Almirall, Amgen, Eli Lilly, Galderma,  
87 Leo Pharma, Medac, Novartis, Pfizer and Sanofi-Regeneron.

88 CD: investigator and/or consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Novartis, Pfizer  
89 and Sanofi-Regeneron.

90 MV: investigator, consultant and/or speaker for AbbVie, Almirall, Biogen, Galderma, Eli Lilly,  
91 Boehringer Ingelheim, Medac, Janssen Cilag and Bristol Myers Squibb.

92 MT: none

93 JS: personal fees from AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Sanofi-  
94 Genzyme.

95 SB: investigator or speaker for AstraZeneca, Almirall, Sanofi-Genzyme, AbbVie, Novartis, Janssen,  
96 Leo Pharma, Pfizer, Eli Lilly, UCB Pharma, Chiesi.

97 DSS: investigator and/or consultant and/or speaker for AbbVie, Almirall, Amgen, AstraZeneca, Eli  
98 Lilly, Galderma, Leo Pharma, Novartis, Pfizer and Sanofi-Regeneron.

99

100

101 **IRB approval status:** approved by the organization Commission Nationale de l'Informatique et des  
102 Libertés (CNIL, n° DEC20-312). No opposition to the use of patients' deidentified records was  
103 obtained for this noninterventional study, according to French legislation.

104  
105 **Clinicaltrials.gov ID:** NCT04761978

106  
107 **Reprint requests:** Delphine Staumont-Sallé

108  
109 **Manuscript word count:** 495

110 **References:** 4

111 **Figures and tables:** 2 (2 Tables)

112 **Supplementary figures:** 0

113 **Supplementary tables:** 2

114 **Attachments:** CNIL approval DEC20-312 (December 18, 2020) and clinicaltrials.gov ID.

115 **Patient Consent on File:** Consent for the publication of recognizable patient photographs or other  
116 identifiable material was obtained by the authors and included at the time of article submission to  
117 the journal stating that all patients gave consent with the understanding that this information may be  
118 publicly available.

119  
120 **Keywords:** atopic dermatitis; adults; JAK inhibitors; baricitinib; upadacitinib; real-life study.

121  
122  
123  
124  
125  
126  
127 **Body of manuscript:**

128 JAK inhibitors (JAKis) are newly available drugs for the treatment of moderate-to-severe atopic  
129 dermatitis (AD). Their efficacy and safety have been demonstrated in clinical trials<sup>1-4</sup>, but there is  
130 little published data from real-life practice. Upadacitinib (UPADA), a JAK1-selective inhibitor, has  
131 been available for use in France in adolescents and adults with moderate-to-severe AD in  
132 accordance with the French Early Access Program for patients who failed treatment due to

inefficiency or intolerance or alternate treatments were contraindicated (e.g., cyclosporine (CyA), dupilumab). A second JAKi, baricitinib (BARI) which targets JAK1/JAK2, has been available since March 2021 in adult AD patients after failed cyclosporine (CyA) treatment. We assessed the effectiveness and tolerance of JAKis in real life by conducting a multicenter retrospective cohort that included the first AD patients who received UPADA and BARI from March 2021 to January 2022. The primary outcome was the percentage of patients obtaining an Investigator's Global Assessment (IGA) score at 0, 1 or -2 at 3 ( $\pm$  1) months (M3) compared with baseline. The secondary outcomes were Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), Pruritus Numerical Rating Scale (PNRS), and Dermatological Life Quality Index (DLQI) scores at M3 and at 6 ( $\pm$  1) months (M6). All adverse events (AEs) during the study period were recorded. 100 patients were enrolled from 18 centers: 54 treated with UPADA at 15 mg/day, 12 with UPADA at 30 mg/day, and 34 with BARI at 4 mg/day. Patient characteristics are detailed in **Supplementary Table I** (<https://data.mendeley.com/datasets/5zw326gw6v/1>). Most patients had severe AD (median IGA at baseline, 3; IQR 3;4) and had previously received a mean number of 3 types of systemic drugs before JAKi introduction (methotrexate in 56.6%, CyA in 72% and dupilumab in 78%), interrupted for inefficacy and/or poor tolerance. An IGA score at 0, 1 or -2 compared with baseline was reached at M3 for 33/54 (61.1%), 11/12 (91.7%) and 14/34 (41.2%) patients receiving UPADA 15 mg, UPADA 30 mg or BARI 4 mg, respectively. The median decrease in PNRS at M3 was -3 (IQR -5.5;-1.5), -5 (-7;-1) and -2 (-3;0) in patients receiving UPADA 15 mg (data available for 24 patients), UPADA 30 mg (6 patients) and BARI 4 mg (19 patients), respectively. Other outcomes measured at month 3 and month 6 are shown in **Table I**. The median follow-up duration was 3 months (IQR 3;6). Overall, 60 patients presented at least 1 AE, the most frequent being increased blood levels of cholesterol (23.2%) or triglycerides (18.2%), facial papular eruption (12.9%), increased ALAT and/or ASAT (11.1%) and herpes infection (6.4%) (**Table II**). No thromboembolic events were observed. JAKis were stopped in 18 patients (9 patients taking UPADA 15 mg, 1 taking UPADA 30 mg and 8 taking BARI 4 mg), primarily for drug inefficacy (9/21) and/or for AE (6/21) (**Supplementary Table**

159 **II) (<https://data.mendeley.com/datasets/5jy3c6jrrr/1>).** In summary, this real-life study highlighted  
160 the effectiveness of JAKis in a population of AD patients recalcitrant to conventional systemics and  
161 biologics and demonstrated a good short-term safety profile.

162 **References:**

- 163 1- Guttman-Yassky E, Teixeira HD, Simpson EL et al. Once-daily upadacitinib versus placebo  
164 in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and  
165 Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.  
166 Lancet 2021 ;397:2151-68.
- 167 2- Blauvelt A, Teixeira HD, Simpson EL et al. Efficacy and safety of upadacitinib vs dupilumab  
168 in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA  
169 Dermatol 2021;157:1047-55.
- 170 3- Simpson EL, Lacour JP, Spelman L et al. Baricitinib in patients with moderate-to-severe  
171 atopic dermatitis and inadequate response to topical corticosteroids: results from two  
172 randomized monotherapy phase III trials. Br J Dermatol 2020;183:199-200.
- 173 4- Reich K, Kabashima K, Peris K et al. Efficacy and safety of baricitinib combined with topical  
174 corticosteroids for treatment of moderate to severe atopic dermatitis: A  
175 randomized clinical trial. JAMA Dermatol 2020;156:1333-43.

**Table I.** Efficacy outcomes reported at 3 months (M3) and 6 months (M6) in patients treated with JAKi.

	Outcomes at M3								Outcomes at M6							
	All patients		Upadacitinib 15 mg		Upadacitinib 30 mg		Baricitinib 4 mg		All patients		Upadacitinib 15 mg #		Upadacitinib 30 mg		Baricitinib 4 mg	
	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)	N	Number of patients achieving score (%)
IGA 0, 1 or 2	100	58 (58%)	54	33 (61.1%)	12	11 (91.7%)	34	14 (41.2%)	30	12 (40%)	24	9 (37.5)	4	3 (75.0)	2	0
SCORAD50	53	28 (52.8%)	30	17 (56.7%)	9	7 (77.8%)	14	4 (28.6%)	17	5 (29.4%)	12	3 (25%)	3	2 (66.7%)	2	0
SCORAD75	53	9 (17.0%)	30	4 (13.3%)	9	4 (44.4%)	14	1 (7.1%)	17	2 (11.8%)	12	1 (8.3%)	3	1 (33.3%)	2	0
SCORAD90	53	5 (9.4%)	30	3 (10%)	9	2 (22.2%)	14	0	17	1 (5.9%)	12	0	3	1 (33.3%)	2	0
EASI50	24	13 (54.2%)	14	6 (42.9%)	7	6 (85.7%)	3	1 (33.3%)	10	5 (50%)	8	3 (37.5%)	2	2 (100%)	0	-
EASI75	24	9 (37.5%)	14	5 (35.7%)	7	4 (57.1%)	3	0	10	5 (50%)	8	3 (37.5%)	2	2 (100%)	0	-
EASI90	24	5 (20.8%)	14	1 (7.1%)	7	4 (57.1%)	3	0	10	1 (10%)	8	0	2	1 (50%)	0	-
	N	Absolute value compared with baseline	N	Absolute value compared with baseline	N	Absolute value compared with baseline	N	Absolute value compared with baseline	N	Absolute value compared with baseline	N	Absolute value compared with baseline	N	Absolute value compared with baseline	N	Absolute value compared with baseline
Median PNRS (Q1;Q3)	49	-3 (-5;-1)	24	-3 (-5.5;-1.5)	6	-5 (-7;-1)	19	-2 (-3;0)	14	-3.5 (-5;0)	12	-3.5 (-5.5;-1.5)	1	3 (3;3)	1	-5 (-5;-5)
Median DLQI (Q1;Q3)	15	-5 (-9;-3)	13	-5 (-8;-3)	2	-11 (-15;-7)	0	-	10	-6.5 (-15;-1)	8	-2 (-12;0)	2	-17 (-19;-15)	0	-

Because the follow-up time was not standardized among the different centers, the IGA, SCORAD, EASI, PNRS and DLQI scores at three months (M3) were defined by the highest (or worst) scores recorded after either two, three or four months of treatment. The same scores at six months (M6) were defined by the highest (or worst) scores recorded after either five, six or seven months of treatment.

# including 13 patients who received upadacitinib 15 mg from M0 to at least M3 and then 30 mg; 4 patients (30.7%) obtained an IGA score of 0-2 at M6.

N: Number of patients with available data. IGA: Investigator's Global Assessment. SCORAD: Scoring Atopic Dermatitis. EASI: Eczema Area and Severity Index. PNRS: Pruritus Numerical Rating Scale. DLQI: Dermatological Life Quality Index. Q1: first quartile. Q3: third quartile. SCORAD50/75/90: Patients achieving 50/75/90% amelioration of SCORAD compared to baseline. EASI 50/70/90: Patients achieving 50/75/90% amelioration of EASI compared to baseline.



**Table II** Adverse events reported during the follow-up period in patients treated with JAK inhibitors.

Adverse event (AE)	All patients		Upadacitinib 15 mg		Upadacitinib 30 mg		Baricitinib 4 mg	
	N patients with data available	Patients, n (%)	N patients with AE	Patients, n (%)	N patients with AE	Patients, n (%)	N patients with AE	Patients, n (%)
At least 1 adverse event	100	60 (60.0)	54	35 # (64.8)	12	6 (50.0)	34	19 (55.9)
At least 1 biological adverse event	99	44 (44.4)	53	25 (47.2)	12	2 (16.7)	34	17 (50.0)
At least 1 clinical adverse event	100	30 (30.0)	54	19 (35.2)	12	4 (33.3)	34	7 (20.6)
Increased* LDL cholesterol or total cholesterol	99	23 (23.2)	53	13 (24.5)	12	1 (8.3)	34	9 (26.5)
Increased* triglycerides	99	18 (18.2)	53	12 (22.6)	12	1 (8.3)	34	5 (14.7)
Facial papular eruptions	93	12 <sup>1</sup> (12.9)	53	9 (17)	9	3 (33.3)	31	0
Increased ALAT and/or ASAT §	99	11 (11.1)	53	6 (11.3)	12	2 (16.7)	34	3 (8.8)
Increased* CPK §	99	8 (8.1)	53	6 (11.3)	12	2 (16.7)	34	0
HSV infections	94	6 (6.4)	54	4 (7.4)	9	2 (22.2)	31	0
Headaches	93	5 (5.4)	54	4 (7.4)	9	0	30	1 (3.3)
Upper airway infections	95	3 (3.2)	54	0	10	0	31	3 (9.7)
Lymphopenia	99	3 (3.0)	53	3 (5.7)	12	0	34	0
Nausea	95	2 (2.1)	54	1 (1.9)	10	0	31	1 (3.2)
Increased* creatinine clearance §	99	2 (2.0)	53	0	12	0	34	2 (5.9)
Neutropenia §	99	2 (2.0)	53	2 (3.8)	12	0	34	0
Diarrhea	95	1 (1.1)	54	0	10	1 (10)	31	1 (3.2)
Abdominal pain	95	1 (1.1)	54	1 (1.9)	10	0	31	0
Cough	93	1 (1.1)	54	1 (1.9)	8	0	31	0
Herpes zoster	95	1 (1.1)	54	1 (1.9)	10	0	31	0
Fever	95	1 (1.1)	54	0	10	1 (10)	31	0
Weight increase	95	1 (1.1)	54	1 (1.9)	10	0	31	0
Anemia §	99	1 (1.0)	53	1 (1.9)	12	0	34	0
Thrombocytosis §	99	1 (1.0)	53	0	12	0	34	1 (2.9)
Other clinical abnormalities <sup>2</sup>	95	15 (15.7)	54	7 (12.3)	10	2 (20)	31	6 (19.4)
Other biological abnormalities <sup>3</sup> §	99	12 (12.1)	53	6 (11.3)	12	1 (8.3)	34	5 (14.7)

# including 13 patients who received upadacitinib 15 mg from M0 to at least M3 and then 30 mg; 4 patients (30.7%) obtained an IGA score of 0-2 at M6.

\* increased according to local laboratory threshold values

<sup>1</sup> including 6 acne and 6 papulopustular eruptions

<sup>2</sup> including myalgia, asthenia, urticaria, chronic leg ulceration, wart, dermatophytosis, chest pain, dyspnea, molluscum contagiosum, folliculitis, gonalgia, urinary tract infection, facial edema, scalp pruritus, impetigo, dyspepsia, and dizziness.

<sup>3</sup> including C reactive protein elevation, monocytosis, hyperbasophilia, and eosinophilia.

225 § all cases asymptomatic

226 N: Number of patients with available data. LDL: low-density lipoprotein. ALAT (alanine aminotransferase) and/or  
227 ASAT (aspartate aminotransferase). CPK: creatine phosphokinase

228

229

230

Journal Pre-proof